Evidence mapPaperPMID 39377039Full record

ReviewStem cells international2024

Advancements and Innovative Strategies in Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cell Therapy: A Comprehensive Review.

Xiaoyu Shi, Kun Zhang, Fengshi Yu, Qi Qi, Xiaoyu Cai, Yu Zhang

Abstract readReview
In one paragraph

Review in Stem cells international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Stem cells therapy molecular tracking - the special focus on nuclear medicine.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026
    Review
  2. Induced pluripotent stem cells in the treatment of ischemic stroke.Journal of translational internal medicine · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoyu ShiState Industrial Base for Stem Cell Engineering Products, Tianjin 300384, China.
Kun ZhangState Industrial Base for Stem Cell Engineering Products, Tianjin 300384, China.
Fengshi YuState Industrial Base for Stem Cell Engineering Products, Tianjin 300384, China.
Qi QiState Industrial Base for Stem Cell Engineering Products, Tianjin 300384, China.
Xiaoyu CaiState Industrial Base for Stem Cell Engineering Products, Tianjin 300384, China.
Yu ZhangVCANBIO Cell and Gene Engineering Corp. Ltd., Tianjin, China.ORCID https://orcid.org/0000-0002-1297-2742

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effectiveness and safety of mesenchymal stem cell (MSC) therapy have been substantiated across various diseases. Nevertheless, challenges such as the restricted

Identifiers

PMID39377039
PMCPMC11458320

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.